Jamjoom Pharma, a leading Saudi pharmaceutical organization, and Althera Laboratories, a company dedicated to developing and commercialising innovative therapies for cardiovascular and metabolic diseases, have announced a strategic licensing and supply agreement.
This agreement is poised to address the growing need for effective dyslipidemia management in the region, contributing to better patient outcomes and cardiovascular health, said a statement.
Under this agreement, Jamjoom Pharma gets exclusive rights to commercialise in Saudi Arabia and non-exclusive rights for phased expansion across other MEA markets for Althera’s fixed-dose combination of dual-action cholesterol-lowering therapy. The product launch in Saudi Arabia is targeted for 2027, with plans for phased expansion across MEA markets, subject to local regulatory approvals.
This collaboration marks a major milestone for both companies: Jamjoom strengthens its cardiovascular portfolio with a globally recognised and clinically effective therapy, while Althera expands its international footprint in a high-growth region.
The partnership aims to address the region’s growing burden of cardiovascular diseases by increasing access to modern, affordable lipid-lowering treatment, to support patients across MEA.
Dr Tarek Hosni, CEO of Jamjoom Pharma, highlighted that: “Cardiovascular diseases remain to be a leading health concern in Saudi Arabia and the wider MEA region, and this partnership enables us to provide patients across the MEA region with an innovative, evidence-based solution. Expanding access to effective cholesterol management aligns perfectly with our promise to deliver high-quality, affordable medications that improve lives.”
Sanjeev Agarwal, CEO of Althera, added: “This partnership with Jamjoom Pharma is a pivotal step for Althera, allowing us to extend our reach into the rapidly growing MENA region. We are confident that Jamjoom’s deep market understanding and robust capabilities make them the perfect partner to deliver our product to healthcare providers and patients in Saudi Arabia and across MENA. This collaboration is a testament to our dedication to making innovative and affordable cardiovascular treatments more accessible globally.” -TradeArabia News Service
